Leukemia Drug Lumoxiti to be withdrawn From US Market
- Lumoxiti (moxetumomab pasudotox-tdfk) for injection is expected to be permanently discontinued by August 31, 2023, according to a recent communication from the FDA.
- Lumoxiti, a CD22-directed cytotoxin, was approved by the FDA in September 2018 for the treatment of adults with R/R hairy cell leukemia who received at least 2 prior systemic therapies.
- The decision to remove Lumoxiti from the US market was related to its very low clinical uptake due to the availability of other treatment options and not related to the safety or efficacy of the drug.
- Physicians are advised not to initiate new treatment with Lumoxiti.
- The postmarketing study evaluating the safety of Lumoxiti (ClinicalTrial.gov Identifier: NCT04125290) will also be terminated.
Share:
More News
“The initial efficacy data from the Part C studies are consistent with the encouraging efficacy signals we previously reported for Parts A and B of THIO-101, including an 88% disease control rate in third-line NSCLC patients. This measure of efficacy is close to triple the reported outcome for standard-of-care chemotherapy
“Patients with non-muscle invasive bladder cancer continue to face a significant risk of disease recurrence despite available treatment options,” said Mark Schoenberg, M.D., Chief Medical Officer of UroGen. “UGN-501 is an investigational next-generation oncolytic virus designed to selectively destroy tumor cells while generating an anti-tumor immune response. FDA clearance of
“Whitehawk has established strong expertise in ADC technology and oncology drug development,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “This collaboration further expands the application of Biocytogen’s fully human bispecific antibodies in ADC development. We look forward to supporting the efficient advancement of multiple programs by contributing high-quality
Hesham Abdullah, Senior Vice President, Global Head Oncology, R&D, GSK, said: “The AZUR-1 results support the potential for dostarlimab to transform treatment for dMMR/MSI-H locally advanced rectal cancer. For many patients today, rectal cancer treatment comes with the tolerability burden and lasting impacts from chemotherapy, radiation and surgery. These data